fda halts glp-1 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA restricts non-approved compounded GLP-1

Figure 5 A meta-analysis of clinical studies indicated that treatment with GLP-1RAs of obese patients with T2MD did not increase the risk of breast tumors, nor did it increase the risk of acute pancreatitis, pancreatic cancer, and overall tumor neoplasia (207209)

Eur Heart J 2006;27:23872393

3 Results 3.1 Participant characteristics Baseline characteristics were analyzed for 20 participants and are presented as mean SD or percentages in Table 1

The GLP-1 Supply Tracker is free and open access for any patient, provider, or other healthcare stakeholder

See what a recent study found in the "What It Does" sections of our Calcium Supplements Review and Vitamin D Supplements Review